Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

01.12.2025

1 Adv Sci (Weinh)
1 Antioxidants (Basel)
1 ArXiv
1 Biochem Pharmacol
1 Biology (Basel)
1 Biomark Med
1 BJU Int
1 BMC Cancer
1 BMC Urol
1 BMC Vet Res
2 BMJ Case Rep
1 BMJ Open
1 Cancers (Basel)
1 Cell Death Dis
8 Clin Genitourin Cancer
1 Clinics (Sao Paulo)
1 Crit Rev Oncol Hematol
1 Digit Health
1 Discov Oncol
1 Dose Response
1 Eur Urol Oncol
1 Eur Urol Open Sci
1 Expert Opin Drug Saf
1 Fr J Urol
1 Front Immunol
1 Future Cardiol
1 Gene
2 Hereditas
1 Indian J Surg Oncol
1 Int J Biol Sci
1 Int J Surg
1 J Biochem Mol Toxicol
1 J Chemother
1 J Clin Biochem Nutr
1 J Clin Med
1 J Exp Clin Cancer Res
1 J Immunother Cancer
1 J Microbiol
1 J Nanobiotechnology
1 J Transl Med
1 J Urol
1 Medicina (Kaunas)
1 Medicine (Baltimore)
1 medRxiv
1 Mutat Res
1 NPJ Precis Oncol
1 Pathologie (Heidelb)
1 Per Med
5 Sci Rep
1 Urol Oncol
1 World J Urol


    Adv Sci (Weinh)

  1. TU S, Du W, Luo Y, Shi J, et al
    YKT6 Promotes Bladder Cancer Progression by Stabilizing beta-catenin Through USP7-Mediated Deubiquitination.
    Adv Sci (Weinh). 2025 Nov 26:e07166. doi: 10.1002/advs.202507166.
    >> Share


    Antioxidants (Basel)

  2. CIUMMO V, Ciafarone A, Altamura S, Lombardi F, et al
    Exploring the Anticancer Potential of the Multistrain Probiotic Formulation OxxySlab in Bladder Cancer Cell Lines.
    Antioxidants (Basel). 2025;14:1282.
    >> Share


    ArXiv

  3. OLUMOYIN K, Rejniak K
    Modeling Adoptive Cell Therapy in Bladder Cancer from Sparse Biological Data using PINNs.
    ArXiv [Preprint]. 2025 Oct 15:arXiv:2510.13431.
    >> Share


    Biochem Pharmacol

  4. TANG S, Liu Y, Jin B, Zhang T, et al
    LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1.
    Biochem Pharmacol. 2025;243.
    >> Share


    Biology (Basel)

  5. ZHANG W, Zhou K, Chen P, Du X, et al
    Phase Separation Competent TIA1 Couples Glycolytic Shutdown to CD8(+) T-Cell Activation and Shapes the Efficacy of Intravesical BCG in Bladder Cancer.
    Biology (Basel). 2025;14:1576.
    >> Share


    Biomark Med

  6. JIN T, Liu H, Li S, Chen H, et al
    A CT-based deep learning radiomics model for predicting HER2 expression and prognosis in non-muscle-invasive bladder cancer.
    Biomark Med. 2025 Nov 23:1-10. doi: 10.1080/17520363.2025.2590778.
    >> Share


    BJU Int


  7. Correction to "Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer".
    BJU Int. 2025 Nov 24. doi: 10.1111/bju.70090.
    >> Share


    BMC Cancer

  8. ZHAO Y, Li P, Shen Z, Yao S, et al
    Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence.
    BMC Cancer. 2025;25:1796.
    >> Share


    BMC Urol

  9. YAMAZAWA A, Tsuchiya M, Imai S, Ikegami K, et al
    Survey of perioperative treatment in muscle-invasive bladder cancer using Japanese hospital-based claims database.
    BMC Urol. 2025 Nov 24. doi: 10.1186/s12894-025-01995.
    >> Share


    BMC Vet Res

  10. MUSCATELLO LV, D'Annunzio G, Franceschini T, Tugnoli C, et al
    Tumor immune microenvironment and immune phenotypes in PD-L1-tested canine urothelial carcinoma.
    BMC Vet Res. 2025;21:681.
    >> Share


    BMJ Case Rep

  11. CAI C, Mancini J, Zhang S, Heymann J, et al
    Intravesical BCG for bladder cancer treatment complicated by disseminated BCG (BCGosis) with pericardial effusion and tamponade.
    BMJ Case Rep. 2025;18:e268921.
    >> Share

  12. CHAN AW, Chiccarine A, Saxena S, Choi JW, et al
    Pan-urethral condyloma acuminatum in a bladder cancer patient.
    BMJ Case Rep. 2025;18:e269439.
    >> Share


    BMJ Open

  13. FANG CW, Shau WY, Fan SZ, Chueh JS, et al
    Comparison of spinal versus general anaesthesia in high-risk non-muscle invasive bladder cancer: study protocol for a randomised controlled trial.
    BMJ Open. 2025;15:e107824.
    >> Share


    Cancers (Basel)

  14. PINTON P
    Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions.
    Cancers (Basel). 2025;17:3631.
    >> Share


    Cell Death Dis

  15. MAKABE S, Hoshi K, Kaneko H, Masuishi Y, et al
    MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cells.
    Cell Death Dis. 2025;16:868.
    >> Share


    Clin Genitourin Cancer

  16. OH E, Chua Y, Bahar P, Accardo ML, et al
    Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma.
    Clin Genitourin Cancer. 2025;23:102451.
    >> Share

  17. JAIN P, Naqvi SAA, Tripathi N, Oberoi JK, et al
    Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis.
    Clin Genitourin Cancer. 2025;23:102453.
    >> Share

  18. CHE G, Zhao X, Luo R, Yu Q, et al
    Macrophage Cell and Diagnostic Biomarkers in BLCA: Integrating Machine Learning With Single-Cell Analysis.
    Clin Genitourin Cancer. 2025;23:102447.
    >> Share

  19. STEIDLE M, Malshy K, Hunt TC, Cheng Z, et al
    Study Endpoint Fulfillment and FDA Approval Success in Phase III Clinical Trials of Genitourinary Malignancies.
    Clin Genitourin Cancer. 2025;23:102436.
    >> Share

  20. DE ANGELIS M, Siech C, Jannello LMI, Di Bello F, et al
    Rates of Secondary Bladder and Rectal Cancers After External Beam Radiation for Prostate Cancer According to Age and D'amico Risk Groups in A Contemporary Cohort.
    Clin Genitourin Cancer. 2025;23:102429.
    >> Share

  21. ROBESTI D, Micheli F, Rai SN, Fallara G, et al
    Addressing Uneven Treatment Discontinuation Rate in the Chemotherapy Arm of the EV-302 Phase 3 Randomized Clinical Trial: Implications for Outcome Interpretation.
    Clin Genitourin Cancer. 2025;23:102423.
    >> Share

  22. HOF JP, Kiemeney LALM, Aben KKH, van der Heijden AG, et al
    Recurrence Patterns in a Large Contemporary Cohort of Patients With Non-Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2025;24:102464.
    >> Share

  23. CHOW RD, Mamtani R
    Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma.
    Clin Genitourin Cancer. 2025;23:102417.
    >> Share


    Clinics (Sao Paulo)

  24. GALLUCCI FP, de Camargo JA, Viana NI, Pimenta RCA, et al
    CRISPR/Cas9-mediated MMP-9 silencing inhibits bladder cancer T24 cell invasion and migration in vitro.
    Clinics (Sao Paulo). 2025;80:100842.
    >> Share


    Crit Rev Oncol Hematol

  25. ANSAB M, Rath S, Ishaque G, Araib E, et al
    Survival outcomes with enfortumab vedotin-containing regimens in metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Crit Rev Oncol Hematol. 2025;216:104945.
    >> Share


    Digit Health

  26. PAN X, Wen L, Li Y, Zhang Y, et al
    LLM-BCgrading: Large language model-based Chinese medical long text classification for bladder cancer grade prediction.
    Digit Health. 2025;11:20552076251393290.
    >> Share


    Discov Oncol

  27. BI C, Li K, Yang Y, Shi Y, et al
    Identification of potential bladder cancer drug targets through Mendelian randomization and molecular docking.
    Discov Oncol. 2025;16:2172.
    >> Share


    Dose Response

  28. LI C, Lv G, Yue Y, Ma G, et al
    Piperine Targets the FANCL/UBE2T Complex to Inhibit the FA Pathway and Sensitize Bladder Cancer to Cisplatin.
    Dose Response. 2025;23:15593258251404060.
    >> Share


    Eur Urol Oncol

  29. MARIAPPAN P, Hart-Brooke J, Sparks R, Lord-McKenzie T, et al
    Bladder EpiCheck triggered Photodynamic Diagnosis biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy.
    Eur Urol Oncol. 2025 Nov 27:S2588-9311(25)00295.
    >> Share


    Eur Urol Open Sci

  30. FINATI M, Schiavone N, Barone B, Contieri R, et al
    Refining Active Surveillance Eligibility in Intermediate-risk Non-muscle-invasive Bladder Cancer: The Impact of Time to First Recurrence.
    Eur Urol Open Sci. 2025;82:155-159.
    >> Share


    Expert Opin Drug Saf

  31. XU B, Zhang T, He Y, Jiang A, et al
    Impact of sodium glucose cotransporter 2 inhibitors on bladder cancer and breast cancer: a pharmacovigilance analysis and Mendelian randomization study.
    Expert Opin Drug Saf. 2025 Nov 27:1-10. doi: 10.1080/14740338.2025.2595727.
    >> Share


    Fr J Urol

  32. DOIZI S, Abid N, Traxer O, Panthier F, et al
    The role of lasers in the management of bladder tumors.
    Fr J Urol. 2025;35:102970.
    >> Share


    Front Immunol

  33. BROCHIER W, Nguyen S, Cesson V, Bricard O, et al
    Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients.
    Front Immunol. 2025;16:1627914.
    >> Share


    Future Cardiol

  34. SCHOETTLER FI, Fatehi Hassanabad M, Webb NA, Clark J, et al
    Intraoperative urothelial carcinoma tumor thrombus embolization to the heart: a case report.
    Future Cardiol. 2025;21:879-881.
    >> Share


    Gene

  35. FRASCOLLA C, Mastroianni R, Simone G, Blandino G, et al
    The role of 3D preclinical models in the Era of precision medicine: A bladder cancer perspective.
    Gene. 2025;979:149919.
    >> Share


    Hereditas

  36. XIAOHUI Y, Jie L, Jiangqiao Z
    Coptisine regulates PI3K/AKT pathway to block bladder cancer progression: a study based on network pharmacology, in vitro and in vivo assays.
    Hereditas. 2025;162:232.
    >> Share

  37. ZHU K, Zhang Z, Li T, Sun Y, et al
    Integrative multi-omics and single-cell transcriptomics reveal ARHGEF12 driving chemoresistance in bladder cancer.
    Hereditas. 2025;162:234.
    >> Share


    Indian J Surg Oncol

  38. DASH NR, Mohapatra V, Madhusudan KS, Pal S, et al
    Role of Portal Vein Embolization Alone in Surgical Management of Locally Advanced Gall Bladder Cancer (PROVE-GBC): A Prospective Clinical Trial.
    Indian J Surg Oncol. 2025;16:1143-1151.
    >> Share


    Int J Biol Sci

  39. XIONG S, Fan J, Huang C, He S, et al
    Single-cell and spatial transcriptomic analysis reveal cellular heterogeneity and cancer cell-intrinsic major histocompatibility complex II expression in urothelial carcinoma.
    Int J Biol Sci. 2025;21:6649-6673.
    >> Share


    Int J Surg

  40. ZENG S, He W, Liu L, Ying Y, et al
    Chromosomal instability-guided urine sediment analysis enables non-invasive monitoring of minimal residual disease in bladder cancer.
    Int J Surg. 2025 Nov 10. doi: 10.1097/JS9.0000000000003865.
    >> Share


    J Biochem Mol Toxicol

  41. YUAN F, Li X, Hong C, Huang X, et al
    Synergistic Anticancer Effects of COL6A1 Downregulation and the PD1 Inhibitor Pembrolizumab in Bladder Cancer.
    J Biochem Mol Toxicol. 2025;39:e70621.
    >> Share


    J Chemother

  42. HAN Y, Wang S, Xia R, Zhou B, et al
    USP54 suppresses bladder cancer proliferation, stemness, and cisplatin resistance via deubiquitination-mediated stabilization of SIRT6.
    J Chemother. 2025 Nov 26:1-13. doi: 10.1080/1120009X.2025.2591510.
    >> Share


    J Clin Biochem Nutr

  43. MO Q, Lu Y, Wu J, Zhang X, et al
    DNA methylation of CA10 regulates the proliferation and metastasis of bladder cancer.
    J Clin Biochem Nutr. 2025;77:240-248.
    >> Share


    J Clin Med

  44. GHOLAMI SS, Movassaghi M, Homayoun S, Vasdev N, et al
    Clinical Experience with URO17((R)) in the Diagnosis and Surveillance of Bladder Cancer.
    J Clin Med. 2025;14:8108.
    >> Share


    J Exp Clin Cancer Res

  45. WANG T, Ma X, Wang Y, Liu H, et al
    Lactate-driven lactylation of HNRNPA1 orchestrates PKM2 splicing and glycolytic reprogramming in bladder cancer.
    J Exp Clin Cancer Res. 2025 Nov 22. doi: 10.1186/s13046-025-03591.
    >> Share


    J Immunother Cancer

  46. CAI T, Feng T, Zhang W, Ge Q, et al
    Neutrophil extracellular traps-STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer.
    J Immunother Cancer. 2025;13:e012736.
    >> Share


    J Microbiol

  47. TRAN TA, Lee HY, Choi HW
    Metabolite-mediated mechanisms linking the urinary microbiome to bladder cancer.
    J Microbiol. 2025;63:e2509001.
    >> Share


    J Nanobiotechnology

  48. ZHANG Y, Yang E, Zhang X, Shi Y, et al
    A novel sono-activatable nanoreactor induces precision intratumoral juglone generation and caspase 3/GSDME-mediated pyroptosis for treatment of bladder cancer.
    J Nanobiotechnology. 2025 Nov 22. doi: 10.1186/s12951-025-03855.
    >> Share


    J Transl Med

  49. TIAN H, Song J, Cong J, Zhang Z, et al
    Protein kinase D2-mediated maintenance complex component 2 phosphorylation promotes bladder cancer progression.
    J Transl Med. 2025;23:1357.
    >> Share


    J Urol

  50. GONZALEZ-PADILLA DA, Subiela JD, Villacampa-Auba F
    Immune checkpoint inhibitors for high-risk non-muscle invasive bladder cancer: Lessons learnt from the CREST and POTOMAC trials.
    J Urol. 2025 Nov 25:101097JU0000000000004864. doi: 10.1097/JU.0000000000004864.
    >> Share


    Medicina (Kaunas)

  51. RATHORE V, Lin WW
    Decoding SIGLEC12 in Bladder Cancer: In Silico Profiling of Expression, Tumor-Immune Interactions, and Prognostic Impact.
    Medicina (Kaunas). 2025;61:1894.
    >> Share


    Medicine (Baltimore)

  52. YANG J, Xu Z, Tao B, Zhao Y, et al
    Causal insights into immune cell profiles, plasma metabolites, and bladder cancer: A Mendelian randomization approach.
    Medicine (Baltimore). 2025;104:e46062.
    >> Share


    medRxiv

  53. GREENBERG ZF, Hutchinson TE, Kahn J, Graim KS, et al
    Urinary extracellular vesicles for high-precision bladder cancer subtyping and prognosis.
    medRxiv [Preprint]. 2025 Oct 17:2025.10.14.25338041.
    >> Share


    Mutat Res

  54. YUAN Q, Liu B, Yan W, Li H, et al
    FOXA2 promotes glutamine metabolism to facilitate the malignant development of bladder cancer by transcriptionally increasing GLS1 expression.
    Mutat Res. 2025;831:111920.
    >> Share


    NPJ Precis Oncol

  55. SHEN J, Li Z, Wang R, Ding G, et al
    Bladder cancer diagnostic and prognostic models from DNA methylation by multi algorithm machine learning.
    NPJ Precis Oncol. 2025 Nov 26. doi: 10.1038/s41698-025-01195.
    >> Share


    Pathologie (Heidelb)

  56. PANNHAUSEN J, Chughtai AA, Melzer MK, Ma Y, et al
    POLQ and DNA-PK inhibition in muscle-invasive bladder cancer : Enhancing radiosensitivity with novel DNA damage response inhibitors to improve radiotherapy outcomes.
    Pathologie (Heidelb). 2025 Nov 26. doi: 10.1007/s00292-025-01507.
    >> Share


    Per Med

  57. JAIN A, Dey S, Garg D, Singh H, et al
    A multilevel ensemble model for predicting mutation types in bladder cancer.
    Per Med. 2025 Nov 26:1-10. doi: 10.1080/17410541.2025.2592530.
    >> Share


    Sci Rep

  58. ALSAYEH AR, Abdelrazek EM, Oraby AH, Shokeir AA, et al
    Red single wavelength emitting up-conversion nanoparticles modulate cellular dynamics and gene expression in T24 bladder cancer cells.
    Sci Rep. 2025;15:42539.
    >> Share

  59. KOBAYASHI T, Kitamura H, Furukawa Y, Shono M, et al
    JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.
    Sci Rep. 2025;15:41773.
    >> Share

  60. KANESAKA M, Sazuka T, Kita Y, Fukuhara H, et al
    Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer.
    Sci Rep. 2025;15:41872.
    >> Share

  61. LI M, Li Z, Xu C, Chen Y, et al
    Semi-supervised medical image segmentation of bladder tumors based on supervised branches and uncertainty estimation.
    Sci Rep. 2025;15:41517.
    >> Share

  62. YU SY, Li HY, Wang CY, Wang WJ, et al
    Tumor-derived lactate fuels the STAT3-LCN2 pathway to promote bladder cancer malignancy and chemoresistance.
    Sci Rep. 2025;15:41610.
    >> Share


    Urol Oncol

  63. FINOCCHIARO A, Contieri R, Piccolini A, Brin P, et al
    Assessing risk stratification in Bacillus Calmette-Guerin-treated high-grade Ta nonmuscle-invasive bladder cancer patients.
    Urol Oncol. 2025 Nov 27:S1078-1439(25)00447.
    >> Share


    World J Urol

  64. SONG JJ, Zhou MT, Lee SZ, Jones JM, et al
    Safety of transurethral resection of bladder tumor in octogenarians: a NSQIP analysis.
    World J Urol. 2025;43:718.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016